Rapid Improvement of Patient-reported CDAI Diary Components by Day 8 in Active Crohnʼs Disease Patients Treated with Certolizumab Pegol

Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), William J. Sandborn(University of San Diego), Mani Khaliq-Kareemi(Dalhousie University), Ole Østergaard Thomsen(University of Copenhagen), Ralph Bloomfield(AstraZeneca (United Kingdom)), Ian C. Lawrance(University of Western Australia)
The American Journal of Gastroenterology
October 1, 2009
10.14309/00000434-200910003-01194
Cited by 2

Related Papers

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k